Novartis’ Sandoz division has announced a new UK headquarters based in Camberley, Surrey.
The global leader in generics and biosimilars announced that it has opened the new building at Watchmoor Park, forming part of the company’s “Transforming Sandoz” strategy, which aims to enable the business to “strengthen its role as a leading provider of medicines to the NHS.”
The company says that the site will be the centre of its UK operations, which encompasses a range of operational functions. It also announced that it is “are hugely excited” to be opening the “new home”, and that “The move is part of our mission to build a long-term future in the UK and to continue working with the NHS to ensure access to generic medicines and biosimilars” said Timothy de Gavre, Sandoz UK country head.
He continued, “Watchmoor Park is the right home for us and our customers; offering convenience, an ideal location and appropriate facilities for our business requirements. As a company, we are on an exciting journey and we look forward to supporting the progress of Watchmoor Park as a thriving
By Anna Smith
Source: PharmaTimes
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.
